Pharmacokinetics and pharmacodynamics of cefovecin in dogs
Authors:
- 2 November 2006
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 29 (6) , 501-511
Abstract
A series ofin vivo,ex vivoandin vitrostudies were conducted to determine the pharmacokinetic and pharmacodynamic properties of cefovecin, a new injectable cephalosporin, in dogs. Absolute bioavailability was determined in a two‐phase cross‐over study in dogs receiving 8 mg/kg bodyweight (b.w.) of cefovecin by either subcutaneous (s.c.) or intravenous (i.v.) route. After s.c. administration, cefovecin was fully bioavailable (100%), the mean maximum plasma concentration (Cmax) was 121 μg/mL and the mean apparent elimination half‐life (t1/2) was 133 h. Clearance was measured to be 0.76 mL/h/kg after i.v. dosing. The concentration of cefovecin in urine measured 14 days after s.c. administration was 2.9 μg/mL. Plasma protein binding was determined by equilibrium dialysis; over concentrations ranging from 10 to 100 μg/mL (i.e. up to the approximateCmaxfollowing an 8 mg/kg dose), protein binding of 98.7% to 96.0% was observed, however, binding was lower at higher concentrations. Total and free concentrations of cefovecin were determined in plasma, transudate and exudate collected from dogs previously implanted subcutaneously with tissue cages. Mean peak concentrations of free cefovecin were almost three times higher in transudate than in plasma and remained above 0.25 μg/mL for 19 days. Theex vivoantibacterial killing activity (vs.Staphylococcus intermedius,MIC0.25 μg/mL) was measured in serum, transudate and exudate collected from dogs which had received 8 mg/kg b.w. of cefovecin subcutaneously. Transudate exhibited higher antimicrobial killing activity than serum. Activity in serum and exudate exhibited a mean reduction in bacterial counts ofS. intermediusof at least three log units up to 72 h postadministration. Bactericidal activity (>3 log10reduction of bacterial counts) was observed in transudate up to 12 days postadministration. The slow elimination and long lastingex vivoantibacterial killing activity following administration of cefovecin are desirable pharmacokinetic and pharmacodynamic attributes for an antimicrobial drug with 14‐day dosing intervals.Keywords
This publication has 19 references indexed in Scilit:
- Antimicrobial Activity and Spectrum of Cefovecin, a New Extended- Spectrum Cephalosporin, against Pathogens Collected from Dogs and Cats in Europe and North AmericaAntimicrobial Agents and Chemotherapy, 2006
- Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogsJournal of Veterinary Pharmacology and Therapeutics, 2005
- Interaction of 31 β-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1European Journal of Pharmaceutics and Biopharmaceutics, 2005
- Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicineJournal of Veterinary Pharmacology and Therapeutics, 2004
- The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibioticsResearch in Veterinary Science, 2002
- β-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine TransporterJournal of Biological Chemistry, 2000
- Penetration of parenterally administered ceftiofur into sterile vs. Pasteurella haemolytica‐infected tissue chambers in cattleJournal of Veterinary Pharmacology and Therapeutics, 1996
- Plasma and urine disposition and dose proportionality of ceftiofur and metabolites in dogs after subcutaneous administration of ceftiofur sodiumJournal of Veterinary Pharmacology and Therapeutics, 1995
- Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection ModelsThe Journal of Infectious Diseases, 1989
- Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal ModelThe Journal of Infectious Diseases, 1988